CD19-directed CAR T cells gain traction
Mené aux Etats-Unis et en Israël sur 108 patients atteints d'un lymphome à grandes cellules B réfractaire ou récidivant, cet essai de phase I/II évalue l'efficacité, du point de vue du taux de réponse, et la toxicité de l'axicabtagène ciloleucel, une immunothérapie à base de cellules CAR-T anti-CD19 (durée médiane de suivi : 27,1 mois)
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has changed the prognosis of patients with relapsed or refractory large B-cell lymphoma. In the past 12 months, two products have been approved by both the US Food and Drug Administration and the European Medicines Agency for use in this setting: axicabtagene ciloleucel, which was approved in the USA in late 2017 on the basis of results of the ZUMA-1 trial, and tisagenlecleucel, which was initially approved in the USA for relapsed or refractory paediatric or young adult B-cell precursor acute lymphoblastic leukaemia in 2017, and subsequently approved for adults with relapsed or refractory diffuse large B-cell lymphoma in early 2018 on the basis of results of the JULIET trial.
The Lancet Oncology , commentaire, 2017